$855 Million is the total value of Rock Springs Capital Management LP's 93 reported holdings in Q4 2014. The portfolio turnover from Q3 2014 to Q4 2014 was 52.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MRK | Sell | MERCK & CO INC NEW | $25,556,000 | -9.2% | 450,000 | -5.3% | 2.99% | -31.4% |
| GILD | Sell | GILEAD SCIENCES INC | $24,036,000 | -37.8% | 255,000 | -29.8% | 2.81% | -53.0% |
| BIIB | Sell | BIOGEN IDEC INC | $15,445,000 | -23.9% | 45,500 | -25.8% | 1.81% | -42.5% |
| FLML | Sell | FLAMEL TECHNOLOGIES SAsponsored adr | $11,563,000 | +9.9% | 675,000 | -8.2% | 1.35% | -16.8% |
| COO | Sell | COOPER COS INC | $8,753,000 | -18.3% | 54,000 | -21.5% | 1.02% | -38.2% |
| ILMN | Sell | ILLUMINA INC | $5,630,000 | -7.2% | 30,500 | -17.6% | 0.66% | -29.7% |
| WCG | Sell | WELLCARE HEALTH PLANS INC | $4,924,000 | +7.0% | 60,000 | -21.3% | 0.58% | -19.1% |
| AGN | Sell | ALLERGAN INC | $3,933,000 | -3.0% | 18,500 | -18.7% | 0.46% | -26.6% |
| CTLT | Sell | CATALENT INC | $3,725,000 | -26.0% | 133,600 | -33.5% | 0.44% | -44.0% |
| CBAY | Sell | CYMABAY THERAPEUTICS INC | $983,000 | -52.1% | 100,000 | -66.7% | 0.12% | -63.7% |
| AAVL | Exit | AVALANCHE BIOTECHNOLOGIES IN | $0 | – | -7,198 | -100.0% | -0.04% | – |
| ARWR | Exit | ARROWHEAD RESH CORP | $0 | – | -115,000 | -100.0% | -0.26% | – |
| VSAR | Exit | VERSARTIS INC | $0 | – | -124,255 | -100.0% | -0.36% | – |
| THRX | Exit | THERAVANCE INC | $0 | – | -190,000 | -100.0% | -0.50% | – |
| FEIC | Exit | FEI CO | $0 | – | -47,000 | -100.0% | -0.55% | – |
| CVD | Exit | COVANCE INC | $0 | – | -46,000 | -100.0% | -0.56% | – |
| A | Exit | AGILENT TECHNOLOGIES INC | $0 | – | -72,500 | -100.0% | -0.64% | – |
| CAH | Exit | CARDINAL HEALTH INC | $0 | – | -92,250 | -100.0% | -1.07% | – |
| ATHN | Exit | ATHENAHEALTH INC | $0 | – | -67,750 | -100.0% | -1.38% | – |
| PCRX | Exit | PACIRA PHARMACEUTICALS INC | $0 | – | -102,000 | -100.0% | -1.53% | – |
| TMO | Exit | THERMO FISHER SCIENTIFIC INC | $0 | – | -108,500 | -100.0% | -2.04% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-02-17
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| INTUITIVE SURGICAL INC | 43 | Q2 2024 | 4.0% |
| NEUROCRINE BIOSCIENCES INC | 42 | Q2 2024 | 4.8% |
| PACIRA PHARMACEUTICALS INC | 42 | Q2 2024 | 2.6% |
| ULTRAGENYX PHARMACEUTICAL IN | 42 | Q2 2024 | 2.4% |
| ACADIA HEALTHCARE COMPANY IN | 41 | Q2 2024 | 4.4% |
| ASCENDIS PHARMA A/S | 38 | Q2 2024 | 1.3% |
| BIOMARIN PHARMACEUTICAL INC | 38 | Q2 2024 | 1.3% |
| MACROGENICS INC | 38 | Q2 2024 | 0.5% |
| AMICUS THERAPEUTICS INC | 37 | Q2 2024 | 0.6% |
| ADAPTIMMUNE THERAPEUTICS PLC | 37 | Q2 2024 | 1.2% |
View Rock Springs Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Travere Therapeutics, Inc. | May 01, 2024 | 4,411,983 | 5.8% |
| Xilio Therapeutics, Inc. | April 05, 2024 | 3,003,259 | 8.7% |
| Aclaris Therapeutics, Inc. | February 14, 2024 | 2,998,495 | 4.2% |
| AGIOS PHARMACEUTICALS, INC. | February 14, 2024 | 2,152,173 | 3.8% |
| Gamida Cell Ltd.Sold out | February 14, 2024 | 0 | 0.0% |
| Immunocore Holdings plc | February 14, 2024 | 2,661,507 | 5.4% |
| Inozyme Pharma, Inc. | February 14, 2024 | 3,681,174 | 6.0% |
| Mereo BioPharma Group plc | February 14, 2024 | 39,919,255 | 5.7% |
| SPRUCE BIOSCIENCES, INC. | February 14, 2024 | 2,609,125 | 6.4% |
| Spyre Therapeutics, Inc.Sold out | February 14, 2024 | 0 | 0.0% |
View Rock Springs Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-30 |
| 13F-HR | 2024-08-14 |
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-01 |
| SC 13G/A | 2024-04-05 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Rock Springs Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.